BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7446530)

  • 21. Detection of Tay-Sachs disease carriers among individuals with thermolabile hexosaminidase B.
    Peleg L; Goldman B
    Eur J Clin Chem Clin Biochem; 1994 Feb; 32(2):65-9. PubMed ID: 8003579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biochemical genetics of the hexosaminidase system in man.
    Beutler E
    Am J Hum Genet; 1979 Mar; 31(2):95-105. PubMed ID: 377957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The biochemical basis of gangliosidoses.
    Sandhoff K; Conzelmann E
    Neuropediatrics; 1984 Sep; 15 Suppl():85-92. PubMed ID: 6242704
    [No Abstract]   [Full Text] [Related]  

  • 24. Nomenclature of GM2-gangliosidoses.
    Nørby S
    Clin Genet; 1980 May; 17(5):320-2. PubMed ID: 7192191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sandhoff disease: a prevalent form of infantile GM2 gangliosidosis in Lebanon.
    Der Kaloustian VM; Khoury MJ; Hallal R; Idriss ZH; Deeb ME; Wakid NW; Haddad FS
    Am J Hum Genet; 1981 Jan; 33(1):85-9. PubMed ID: 7468596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-locus hexosaminidase genetic compound with juvenile gangliosidosis phenotype: clinical, genetic, and biochemical studies.
    Johnson WG; Cohen CS; Miranda AF; Waran SP; Chutorian AM
    Am J Hum Genet; 1980 Jul; 32(4):508-18. PubMed ID: 6772023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening.
    Triggs-Raine BL; Mules EH; Kaback MM; Lim-Steele JS; Dowling CE; Akerman BR; Natowicz MR; Grebner EE; Navon R; Welch JP
    Am J Hum Genet; 1992 Oct; 51(4):793-801. PubMed ID: 1384323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural history and inherited disorders of a lysosomal enzyme, beta-hexosaminidase.
    Neufeld EF
    J Biol Chem; 1989 Jul; 264(19):10927-30. PubMed ID: 2525553
    [No Abstract]   [Full Text] [Related]  

  • 29. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
    Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
    Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Juvenile Sandhoff Disease: complementation tests with Sandhoff and Tay-Sachs disease using polyethylene glycol-induced cell fusion.
    Wood S
    Hum Genet; 1978 Apr; 41(3):325-9. PubMed ID: 417993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus transformed lymphoid cell lines as a new model system in culture for the study of GM2-gangliosidoses: Tay-Sachs and Sandhoff diseases.
    Maret A; Salvayre R; Negre A; Bes JC; Douste-Blazy L
    Biol Cell; 1985; 53(3):293-6. PubMed ID: 2990625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for a hybrid hexosaminidase isoenzyme in heterozygotes for Sandhoff disease.
    Lowden JA
    Am J Hum Genet; 1979 May; 31(3):281-9. PubMed ID: 463876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gangliosidosis GM2 type 2 (Sandhoff disease)].
    Sánchez-Corona J; Vaca G; González-Flores SA; Villar V; Solé MT; Barajas LO; Velázquez R; Valdez-Luviano J; Cantú JM
    Rev Invest Clin; 1985; 37(1):43-7. PubMed ID: 4001618
    [No Abstract]   [Full Text] [Related]  

  • 34. The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program.
    Rozenberg R; Pereira Lda V
    Sao Paulo Med J; 2001 Jul; 119(4):146-9. PubMed ID: 11500789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mutation mechanism causing juvenile-onset Tay-Sachs disease among Lebanese.
    Hechtman P; Boulay B; Bayleran J; Andermann E
    Clin Genet; 1989 May; 35(5):364-75. PubMed ID: 2527097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel mutations and DNA-based screening in non-Jewish carriers of Tay-Sachs disease.
    Akerman BR; Natowicz MR; Kaback MM; Loyer M; Campeau E; Gravel RA
    Am J Hum Genet; 1997 May; 60(5):1099-106. PubMed ID: 9150157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
    Phaneuf D; Wakamatsu N; Huang JQ; Borowski A; Peterson AC; Fortunato SR; Ritter G; Igdoura SA; Morales CR; Benoit G; Akerman BR; Leclerc D; Hanai N; Marth JD; Trasler JM; Gravel RA
    Hum Mol Genet; 1996 Jan; 5(1):1-14. PubMed ID: 8789434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.
    Lyn N; Pulikottil-Jacob R; Rochmann C; Krupnick R; Gwaltney C; Stephens N; Kissell J; Cox GF; Fischer T; Hamed A
    Orphanet J Rare Dis; 2020 Apr; 15(1):92. PubMed ID: 32295606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Sandhoff disease in a Thai family: clinical and biochemical characterization.
    Sakpichaisakul K; Taeranawich P; Nitiapinyasakul A; Sirisopikun T
    J Med Assoc Thai; 2010 Sep; 93(9):1088-92. PubMed ID: 20873083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of polypeptides serologically and structurally related to hexosaminidase in cultured fibroblasts.
    Tsui F; Mahuran DJ; Lowden JA; Mosmann T; Gravel RA
    J Clin Invest; 1983 Apr; 71(4):965-73. PubMed ID: 6833496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.